Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function

The American Journal of Cardiology
Gian B DanziRoberto Baglini

Abstract

In patients treated with primary coronary angioplasty, the use of abciximab improves microvascular perfusion and enhances the recovery of contractile function. This study compared the effects of the new dose regimen of tirofiban (25-microg/kg bolus followed by an 18-hour infusion at 0.15 microg/kg/min) on left ventricular function with those of abciximab in patients who underwent direct angioplasty. One hundred patients who underwent primary coronary angioplasty were randomized to receive a standard dose of abciximab or a large-dose bolus of tirofiban. The primary end point of the study was change in the infarct-zone wall motion score index between the initial and 30-day follow-up echocardiographic studies. The secondary end points were procedural evaluations before and after Thrombolysis In Myocardial Infarction (TIMI) grade flow, TIMI grade myocardial perfusion, and corrected TIMI frame count. Baseline global and regional ventricular functions were similar in the 2 treatment groups. After the procedure, a TIMI grade 3 flow was obtained in 86% of patients treated with abciximab and 88% of those receiving tirofiban (p = 1.0), whereas TIMI grade 3 myocardial perfusion was present in 70% and 76%, respectively (p = 0.65); correcte...Continue Reading

References

Mar 29, 2002·The New England Journal of Medicine·Gregg W StoneUNKNOWN Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators
Dec 14, 2002·The American Journal of Cardiology·David J SchneiderPeter M DiBattiste
Mar 29, 2003·Current Medical Research and Opinion·Gian B DanziRoberto Baglini

❮ Previous
Next ❯

Citations

Mar 1, 2008·Biologics : Targets & Therapy·Marco ValgimigliGianfranco Percoco
Sep 15, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Brendan Duffy, Deepak L Bhatt
Nov 1, 2007·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Arnoud W J van 't HofJurriën M Ten Berg
Apr 28, 2005·Expert Review of Cardiovascular Therapy·Alberto MenozziDiego Ardissino
May 28, 2011·Expert Review of Cardiovascular Therapy·Giampaolo NiccoliFilippo Crea
Mar 10, 2010·Expert Opinion on Pharmacotherapy·Yahya B JuwanaArnoud W J van 't Hof
Jul 31, 2010·Expert Opinion on Drug Safety·Marco Valgimigli, Matteo Tebaldi
Apr 13, 2007·Expert Opinion on Drug Metabolism & Toxicology·Debabrata Mukherjee, Marco Roffi
Feb 2, 2012·Current Medical Research and Opinion·S H LangJ Kleijnen
Oct 7, 2011·Cardiovascular Therapeutics·Giuseppe De Luca
Jan 31, 2006·American Heart Journal·Adrián V HernándezEwout W Steyerberg
Feb 2, 2008·Journal of the American College of Cardiology·Hitinder S GurmUNKNOWN Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)
Feb 2, 2008·Journal of the American College of Cardiology·David J Moliterno, Khaled M Ziada
Jul 18, 2009·Journal of the American College of Cardiology·Giampaolo NiccoliFilippo Crea
Mar 17, 2005·European Heart Journal·Sigmund SilberUNKNOWN Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Oct 9, 2021·American Journal of Physiology. Heart and Circulatory Physiology·Carmen MethnerSanjiv Kaul

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiogenic Shock

Cardiogenic shock is a devastating consequence of acute myocardial infarction and is associated with an extremely high mortality. Here is the latest research.

Related Papers

© 2022 Meta ULC. All rights reserved